<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>Hindawi Publishing Corporation <br /> Interdisciplinary Perspectives Infectious Diseases <br /> Volume 2014, Article ID 453186, 7 pages <br /> http://dx.doi.org/10.1155/2014/453186 <br />  <br />  <br />  <br />  <br /> Review Article <br /> Serine Proteases Malaria Parasite Plasmodium falciparum: <br /> Potential Antimalarial Drug Targets <br />  <br />            Asrar Alam <br />            Department Biological Sciences, Tata Institute Fundamental Research, Homi Bhabha Road, Colaba, Mumbai-400005, India <br />  <br />            Correspondence addressed Asrar Alam; asraralam22@yahoo.co.in <br />  <br />            Received 25 October 2013; Revised 2 January 2014; Accepted 7 January 2014; Published 11 March 2014 <br />  <br />            Academic Editor: Mary E. Marquart <br />  <br />            Copyright &#194;&#169; 2014 Asrar Alam. This open access article distributed Creative Commons Attribution License, which <br />            permits unrestricted use, distribution, reproduction medium, provided original work properly cited. <br />  <br />            Malaria major global parasitic disease cause enormous mortality morbidity. Widespread drug resistance against <br />            currently available antimalarials warrants identification novel drug targets development new drugs. Malarial proteases <br />            group molecules serve potential drug targets essentiality parasite life cycle stages feasibility <br />            designing specific inhibitors them. Proteases belonging various mechanistic classes P. falciparum, of <br />            serine proteases particular involvement parasite-specific processes egress invasion. In P. <br />            falciparum, number serine proteases belonging chymotrypsin, subtilisin, rhomboid clans found. This review focuses <br />            potential P. falciparum serine proteases antimalarial drug targets. <br />  <br />  <br />  <br />  <br /> 1. Global Malaria Burden Need                                        plant effective antimalarials. Quinoline <br />    Development Novel Antimalarials                                        compound chloroquine widely used drug <br />                                                                              recently. Resistance chloroquine started Africa in <br /> Malaria caused protozoan parasite Plasmodium major                   1980s, causing tremendous resurgence malaria burden <br /> global parasitic disease [1]. Malaria humans caused                 [3, 4]. Chloroquine resistance prompted countries <span id='am-6' about='protege:TO' typeof='owl:Thing'>to</span> <br /> five Plasmodium species, namely, P. falciparum, P. vivax, P.                 adopt sulfadoxine-pyrimethamine (SP) first-line anti- <br /> ovale, P. malariae, P. knowlesi. Of these, P. falciparum              malarial resistant P. falciparum populations selected <br /> the causative agent severe malaria major cause                 quickly Africa, Southeast Asia, South America. It was <br /> malaria-related fatality.                                                    abandoned 5 years use Southeast Asia [5, 6]. <br />     According World Malaria Report 2013,                    Due widespread resistance available antimalarials, <br /> an estimated 207 million clinical cases malaria 2012                   artemisinin-based combination therapies (ACTs) intro- <br /> and estimated 627,000 deaths, 90% deaths                    duced Asia, Africa, South America. The artemisinins <br /> occurring sub-Saharan Africa. International efforts                    potent rapidly acting antimalarials derived the <br /> control malaria resulted significant reduction                    Chinese sweet wormwood plant, Artemisia annua [7, 8]. <br /> malaria-related deaths. Between 2000 2012, malaria-                      Due short duration action, artemisinins cannot <br /> related deaths reduced 29% globally 31%                        administered alone, results recrudescent para- <br /> WHO African Region [2]. Methods used prevent                          sitemia [9]; however, administered ACTs over <br /> spread disease protect individuals areas               days combinations longer-acting antimalar- <br /> malaria endemic include therapeutic prophylactic                      ials forms artemether-lumefantrine, amodiaquine- <br /> drugs, mosquito eradication, prevention mosquito                      artesunate, mefloquine-artesunate [10]. Despite effec- <br /> bites using insecticide-treated nets (ITNs), indoor residual              tiveness ACTs, use artemisinin monotherapy resulted <br /> spray, larval control [2].                                               emergence drug-resistant P. falciparum parasites in <br />     Early antimalarial agents isolated natural prod-               Cambodia-Thailand border region [11, 12]. According to <br /> ucts. Bark cinchona tree extracts wormwood                 WHO, till drug resistance reported three <br />  2                                                                            Interdisciplinary Perspectives Infectious Diseases <br />  <br /> Plasmodium species, P. falciparum, P. vivax, P. malariae         relatively large metabolically active trophozoite <br /> [13].                                                                stage parasite, transforms multinucleated <br />     Currently treatment malaria effected mainly        schizont. Inhibitor-based studies shown cysteine, <br /> the administration chloroquine, SP, ACTs. Prophy-             aspartic, metallo, serine protease activities crucial for <br /> lactic drugs include chloroquine, primaquine, mefloquine,            completion cycle [24]. Several previous studies have <br /> doxycycline, malarone (atovaquone proguanil) [14].           implicated functional role serine proteases egress and <br /> Despite availability antimalarials treatment         invasion blood stages [25&#226;&#8364;&#8220;27]. <br /> and prophylaxis, spread resistance paucity more <br /> antimalarials warrants need identification new <br /> drug targets development novel drugs.                         3. P. falciparum Serine Proteases <br />                                                                      Serine proteases widely dispersed organisms through <br />                                                                      evolution diverse functions. They been <br /> 2. Proteases Antimalarial Drug Targets                            grouped thirteen clans [28]. Chymotrypsin/trypsin-like <br /> Proteases constitute ubiquitous highly abundant group          subtilisin-like serine proteases major clans of <br /> of catalytic regulatory molecules having widespread              serine proteases, highly similar arrangement of <br /> roles living systems. They primarily involved protein      catalytic triad Asp, His, Ser residues radically differ- <br /> turnover constituent amino acids generate            ent protein scaffolds, is, &#240;?&#8250;&#189;/&#240;?&#8250;&#189; chymotrypsin &#240;?&#8250;&#188;/&#240;?&#8250;&#189; <br /> building blocks new proteins digestion dietary            subtilisin [29]. A number serine proteases belonging <br /> proteins higher organisms. Besides, protein activation            chymotrypsin, subtilisin, rhomboid protease clans <br /> by limited proteolysis common means regulation            P. falciparum genome. A list P. falciparum <br /> many physiological processes [15]. Proteases constitute          serine proteases orthologs putative <br /> major virulence factors various parasitic diseases        functions presented Table S1 (Supplementary Materials <br /> schistosomiasis, malaria, leishmaniasis, Chagas disease,         available online http://dx.doi.org/10.1155/2014/453186). <br /> African sleeping sickness. Some well-characterized examples          These pro-teases expressed temporally regulated <br /> of roles proteases parasite pathogenesis include           manner asexual sexual stages parasite life <br /> their involvement invasion host cells, degradation         cycle [30&#226;&#8364;&#8220;32]. Table S2 presents microarray mass <br /> of hemoglobin blood proteins, immune evasion,              spectrometry based expression profiles P. falciparum <br /> and activation inflammation [16]. In context,       serine proteases. Some proteases known be <br /> crucial pathogenic organisms <span id='am-7' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-8' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-10' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-12' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-14' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-15' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-16' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-17' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-18' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-19' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-20' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-21' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-22' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-23' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-25' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-26' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-27' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-28' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-29' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-30' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-32' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-34' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-35' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-36' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-37' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-38' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-44' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-48' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-49' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-53' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-54' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-55' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-57' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-58' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-59' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-60' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-61' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-64' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-66' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-67' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-71' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-73' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-74' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-75' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-77' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-80' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-82' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-83' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-84' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span>survival</span>         essential parasite development erythrocytic and <br /> and diseases cause. Their potential drug targets      exoerythrocytic stages suggesting potential targets <br /> underscored feasibility designing specific inhibitors      therapeutic intervention. <br /> against them. <br />      Proteases recognize optimum peptide sequence             3.1. P. falciparum Chymotrypsin-Like Proteases. Two genes <br /> catalyze cleavage active site. Selective inhibitors       encoding serine proteases chymotrypsin-like clan <br /> targeting active sites developed. Besides active      (PlasmoDB IDs: PF3D7 0807700 PF3D7 0812200) were <br /> sites, exosites allosteric sites participate substrate   identified P. falciparum genome. PF3D7 0807700 homol- <br /> recognition. Hence, selective inhibitors targeting sites       ogous DegP heat shock protein family [33]. Since DegP <br /> can developed [17].                                          acts chaperone low temperature protease at <br />      Protease inhibitors successfully used drugs        elevated temperature, role extracellular process related <br /> against human immunodeficiency virus (HIV) [18]                  invasion unlikely. The second putative chymotrypsin- <br /> hepatitis C virus (HCV) [19] treatment hypertension        like serine protease PF3D7 0812200 possesses PDZ2 domain <br /> [20] coagulopathies [21]. The active sites proteases          trypsin domain. This domain prokary- <br /> have successfully targeted viruses HIV              otic, viral, eukaryotic signaling proteins having GTPase <br /> HCV angiotensin-converting enzyme hypertension                activity [34], known anchor transmembrane proteins <br /> [22, 23]. Targeting active site feasible       cytoskeleton assembly signaling complexes. This <br /> to homology host enzymes. For example,              protease unlikely directly involved invasion. <br /> cancers, development protease inhibitor-based drugs has <br /> been challenging difficulty selectively targeting <br /> the active sites. In cases, allosteric sites           3.2. P. falciparum Subtilisin-Like Proteases. Three genes <br /> targeted achieve goals [17]. Malaria parasite     encoding proteases major clan, subtilisin- <br /> important member parasites phylum Apicomplexa,             like proteases subtilases (clan SB) [35], P. <br /> which invade host cell reside intracellular niche         falciparum genome known PfSUB1, 2, 3. All them <br /> that protected host defenses provides rich             highly expressed late asexual blood stages [31]. Of <br /> source <span id='am-1' about='Thesaurus:Nutrient' typeof='owl:Thing'>nutrient</span>. Asexual erythrocytic life cycle malaria       these, PfSUB1 2 extensively characterized <br /> parasite responsible clinical symptoms malaria.        implicated egress invasion asexual blood <br /> It starts invasion erythrocytes merozoites        stage life cycle parasite [26, 27, 36]. PfSUB3 the <br /> released liver. The intraerythrocytic parasite feeds         characterized member preliminary reports have <br /> host hemoglobin develops small ring stage form              confirmed vitro serine protease activity PfSUB3 <br />  Interdisciplinary Perspectives Infectious Diseases                                                                            3 <br />  <br /> and identified multifunctional parasite protein, pro-        inhibitor, defective merozoites released [51]. <br /> filin, interacting partner [37, 38].                         DPAP3 caused maturation PfSUB1 [27]. The mature <br />                                                                     PfSUB1 caused processing parasitophorous vacuolar <br />                                                                     proteins SERA5 [27] SERA6 [52], implicated <br /> 3.2.1. P. falciparum Subtilisin-Like Protease 1 (PfSUB1).           merozoite egress. <br /> PfSUB1 (PlasmoDB ID: PF3D7 050700 MEROPS iden-                       Merozoite surface protein 1 (MSP1) complex large <br /> tification number S08.012) identified member        glycosylphosphatidylinositol (GPI)-anchored protein com- <br /> P. falciparum subtilases. The primary structure PfSUB1           plex, comprised MSP1 associated partner <br /> classifies small group bacterial-like eukaryotic         proteins MSP6 MSP7. During erythrocyte invasion, <br /> subtilases [29, 35]. PfSUB1 undergoes major intracellular       initial low affinity interaction host cell takes <br /> processing steps maturation. The takes place       place complex [53&#226;&#8364;&#8220;55]. Proteolytic processing <br /> inside lumen endoplasmic reticulum converts          (primary processing) complex necessary initial <br /> earliest detectable 82 kDa form 54 kDa form (p54)            low affinity interaction host parasite and <br /> [39]. The second, brefeldin A-sensitive processing step,     erythrocyte invasion. At later stage, processing <br /> conversion p54 intracellular 47 kDa terminal processing       complex required movement merozoite <br /> product (p47); p54 p47 contain predicted               inside host cell (secondary processing) [36]. PfSUB1 <br /> catalytic domain [40].                                              carries primary processing MSP1 complex in <br />      Expression codon-optimized PfSUB1 gene                   parasitophorous vacuole spatiotemporally regulated <br /> recombinant baculovirus-infected insect cells resulted       manner [56]. Besides, PfSUB1 cleaves number mero- <br /> secretion processed form (p54) [39]. N-terminal radio-       zoite parasitophorous vacuolar proteins [57]. Besides <br /> sequencing vitro translated protein showed            blood stages, SUB1 essential liver developmental <br /> cleavage Asp219 Asn220 sequence Leu-         stages. Conditional <span id='am-85' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-86' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-87' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-88' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-89' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-90' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-91' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-92' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-93' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-95' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-96' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-97' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-98' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-99' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-100' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-101' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-102' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-103' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-104' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-105' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-107' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-108' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-109' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-111' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-112' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-113' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-114' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-115' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-116' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-117' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-122' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-123' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-124' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-125' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-126' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-127' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-128' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-130' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-131' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-135' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-136' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-138' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-139' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-140' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-141' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-143' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-144' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-146' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-147' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-148' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-149' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-150' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-151' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-152' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-154' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-155' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-156' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-158' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-159' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-160' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-161' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-162' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span>knockout</span> Plasmodium berghei SUB1 <br /> Val-Ser-Ala-Asp-Asn-Ile-Asp-Ile-Ser. This highly restricted         (PbSUB1) revealed SUB1, essential early <br /> substrate specificity PfSUB1 suggestive             liver stage development, essential development of <br /> specialized nondegradative biological function           liver stage schizonts production merozoites [58]. Con- <br /> parasite [39, 41]. A substantial fraction insect cell-secreted   ditional mutagenesis studies showed PbSUB1-deficient <br /> p54 bound 31 kDa propeptide (rp31),          merozoites unable egress hepatocytes [59]. <br /> was highly selective, high-affinity inhibitor protease          Recently attempts identify PfSUB1 <br /> with dissociation constant nanomolar range (Ki&#226;&#710;&#188;12.5 nM)          inhibitors. Maslinic acid (MA), low toxic natural penta- <br /> [39]. Truncation 11 residues C-terminal rp31         cyclic triterpene, inhibit P. falciparum blood <br /> substantially reduced inhibition PfSUB1 activity [42]. Since     stage transition ring schizont stage multitargeted <br /> subtilase propeptides specific inhibitors cognate      mechanism. MA inhibit proteolytic pro- <br /> proteases [43&#226;&#8364;&#8220;47], inhibitory peptides proregion       cessing MSP1 complex, probably targeting PfSUB1 <br /> will facilitate designing specific inhibitors protease.   [60]. Characterization PfSUB1 orthologs P. vivax, P. <br />      Many Plasmodium proteins possess structural insertions         knowlesi, P. berghei revealed a <br /> not homologs genera [48, 49].             number unusual features SUB1 substrate binding <br /> These insertions provide targets highly selective           cleft, cleavage sites parasite substrates proteases <br /> therapies P. falciparum. Comparison PfSUB1               conserved. Two peptidyl alpha-ketoamide inhibitors of <br /> primary structure orthologs related bacterial          PfSUB1 inhibited orthologs suggesting small <br /> subtilisins revealed presence high low              molecule inhibitors developed protease <br /> complexity insertions predicted form surface            [61]. A molecular dynamics simulation study binding of <br /> strand loop structures. Site-directed mutagenesis, deletion      known PfSUB1 substrate peptides based prodomain <br /> of loop insertions, strategic replacements             revealed prime nonprime sides scissile <br /> revealed majority loop insertions critical      bond make major contribution binding free energy. <br /> for activity protease [50].                              It comprises peptide residues P4 P2&#243;&#184;&#8364;&#160; making region <br />      PfSUB1 gene refractory deletion             potential designing peptidomimetic inhibitors <br /> in blood stages. It stored apical organelles, distinct       PfSUB1 [62]. Given essentiality parasite blood <br /> <span id='am-3' about='protege:FROM' typeof='owl:Thing'>from</span> involved erythrocyte invasion termed           liver stages, proteolytic activity multiple parasite <br /> &#226;&#8364;&#339;exonemes&#226;&#8364;? [26]. During final stage schizont matu-           proteins, role egress invasion, PfSUB1 qualifies as <br /> ration, discharged parasitophorous vacuole          attractive antimalarial drug target. <br /> (PV) triggered series proteolytic events resulting in <br /> merozoite egress [27]. In attempt identify mediators <br /> of egress, Arastu-Kapur et al. tested effect library    3.2.2. P. falciparum Subtilisin-Like Protease 2. P. falciparum <br /> 1,200 focused serine cysteine protease inhibitors blood      subtilisin-like protease 2 (PfSUB2) (PlasmoDB ID: 248 <br /> stage malaria parasite growth. Using hits library          PF3D7 1136900 MEROPS identification number: <br /> screening, identified PfSUB1 dipeptidyl aminopep-          S08.013) type I 249 transmembrane protein ex- <br /> tidase 3 (DPAP3) primary regulators egress.               pressed late asexual blood stages. Attempts disrupt P. <br /> Inhibition PfSUB1 DPAP3 caused block schizont           berghei ortholog PfSUB2 (PbSUB2) double-crossover <br /> rupture [27] relatively lower concentration            integration unsuccessful, suggesting potential <br />  4                                                                         Interdisciplinary Perspectives Infectious Diseases <br />  <br /> of PfSUB2 drug target [63]. It secreted merozoite    smaller sizes, hydrolyzed increasing concen- <br /> apical organelles &#226;&#8364;&#339;micronemes&#226;&#8364;? plays critical role       tration PfSUB3 [38]. It clear proteolytic <br /> merozoite invasion red blood cells (RBCs) [36].                activity causes maturation PfPRF degradation under <br />     PfSUB2 causes shedding merozoite adhesins MSP1             physiological conditions. Given serine protease activity <br /> and apical membrane antigen 1 (AMA1) juxtamembrane           PfSUB3 multiple physiological functions PfPRF, <br /> site invasion [64]. Cleavage MSP1 PfSUB2             namely, motility, egress, induction, proinflammatory <br /> takes place distal epidermal growth factor- (EGF-)          cytokines, role related processes needs explored <br /> like domain C-terminal called MSP119 [53]. MSP119          [38]. <br /> remains bound merozoite surface only <br /> part MSP1, enters host cell. Cleavage of <br /> AMA1 takes places 29 residues away transmem-             3.3. P. falciparum Rhomboid Proteases. Rhomboid proteins <br /> brane domain, releasing bulk ectodomain. In            intramembranous serine proteases catalytic <br /> this way, juxtamembrane &#226;&#8364;&#339;stub&#226;&#8364;? cognate         triad embedded membrane bilayer, surrounded <br /> transmembrane domain (TMD) cytoplasmic domain                 hydrophilic cavity formed protein ring [70]. Nine <br /> enters host cell [65]. Shedding proteins        rhomboid protease genes P. falciparum genome. <br /> is essential productive invasion [65&#226;&#8364;&#8220;67]. Since PfSUB2        P. falciparum rhomboids largely uncharacterized till date. <br /> causes shedding MSP1 AMA1 mov-                  Two characterized members P. falciparum rhomboids <br /> ing junction erythrocyte invasion, termed         PfROM1 PfPROM4. PfROM1 localizes thread- <br /> &#226;&#8364;&#339;merozoite surface sheddase&#226;&#8364;? (MESH). This protein             like apical organelle blood stage merozoites termed as <br /> not expressed recombinant proteolytically active          &#226;&#8364;&#339;mononeme&#226;&#8364;? [71] surface sporozoites after <br /> form shows MESH activity purified mero-                salivary gland invasion [72]. Plasmodium yoelii ROM1 defi- <br /> zoites. It translocates anterior posterior        cient parasites attenuated erythrocytic hep- <br /> end merozoite actin-dependent movement               atic stages defective parasitophorous vacuole (PV) <br /> as merozoite enters host erythrocyte [36].           development [73]. PfROM1 PfROM4 helped merozoite <br />                                                                   invasion catalyzing intramembrane cleavage the <br />      Like PfSUB1, PfSUB2 undergoes proteolytic process-      merozoite adhesin AMA1 [65, 74] erythrocyte binding <br /> ings parasite, probable maturation          antigen 175 (EBA-175), respectively [75]. PfROM1 and/or 4 <br /> events. The open reading frame encoding PfSUB2         able cleave variety adhesins involved host <br /> vitro translated, revealed 154.8 kDa primary       parasite interaction transmembrane domains [74]. <br /> translated product (SUB2p) underwent rapid conversion          Although initial reports proteases suggestive <br /> 74 kDa intermediate species (SUB2I ) quantita-          importance parasite development, still <br /> tively converted terminal 72 kDa species (SUB2T ) [68].        remain extensively characterized assessed their <br /> The prodomain PfSUB2 selective          therapeutic value. <br /> inhibitor &#226;&#8364;&#339;sheddase&#226;&#8364;? activity [36]. Nuclear magnetic <br /> resonance (NMR) structure PfSUB2 prodomain identified <br /> a likely catalytic domain-binding interface region it, which <br /> could exploited design peptidomimetic inhibitor     4. Conclusion <br /> the protease [69]. Essentiality protease parasite <br />                                                                   P. falciparum serine proteases particular as <br /> survival, involvement RBC invasion, initial find- <br />                                                                   potential antimalarial drug targets role the <br /> ings suggesting feasibility designing inhibitors against <br />                                                                   processes egress invasion erythrocytic preery- <br /> the protease make PfSUB2 promising drug target against <br />                                                                   throcytic stages, critical checkpoints parasite <br /> malaria. <br />                                                                   development blocked. Involvement parasite serine <br />                                                                   proteases processing parasite molecules involved in <br /> 3.2.3. P. falciparum Subtilisin-Like Protease 3. P. falciparum    molecular interactions parasite invasion cleavage <br /> subtilisin-like protease 3 (PfSUB3) (PlasmoDB ID: PF3D7           transmembrane adhesins invasion make them <br /> 0507200 MEROPS identification number: S08.122)             attractive drug targets. Liver stages, clinically silent, <br /> the P. falciparum subtilase. PfSUB3 studied    potential targets drug vaccine intervention due <br /> member P. falciparum subtilases. It highly expressed   low abundance distinct metabolism. Study of <br /> at late asexual blood stages [31]. The full-<span id='am-4' about='xsp:length' typeof='owl:Thing'>length</span> PfSUB3 gene    proteases expressed liver stages exciting area of <br /> encodes 88 kDa protein, 25 kDa C-terminal region           research. A schematic diagram role P. falciparum serine <br /> of shown possess serine protease activity       proteases asexual blood stages liver stages shown in <br /> [37]. Yeast two-hybrid screening revealed parasite profilin   Figure 1. <br /> (PfPRF), cytoskeletal proinflammatory molecule,           Extensive biochemical structural characterization of <br /> interacting partner PfSUB3. PfPRF induce          molecules high throughput screening small <br /> the secretion proinflammatory cytokines IL-12 TNF-         molecules inhibitors lead way development <br /> &#240;?&#8250;&#188; mouse bone marrow-derived dendritic cells. PfSUB3          novel drugs directed proteases. Besides, the <br /> showed proteolytic activity PfPRF in vitro assays           peptidomimetic inhibitors based inhibitory region of <br /> and caused cleavage PfPRF multiple fragments           prodomains developed. <br />  Interdisciplinary Perspectives Infectious Diseases                                                                                          5 <br />  <br />                                                                            [2] WHO, &#226;&#8364;&#339;World malaria report,&#226;&#8364;? 2013. <br />                                                       Subtilisins      [3] J. F. Trape, F. Legros, P. Ndiaye et al., &#226;&#8364;&#339;Chloroquine-resistant <br />                                                     rhomboid proteases         Plasmodium falciparum malaria Senegal,&#226;&#8364;? Transactions the <br />                                                                                Royal Society Tropical Medicine Hygiene, vol. 83, no. 6, p. <br />                                                                                761, 1989. <br />                                   RBC                                      [4] J. R. Zucker, T. K. Ruebush II, C. Obonyo, J. Otieno, C. C. <br />                                                                                Campbell, &#226;&#8364;&#339;The mortality consequences continued use of <br />                                                                                chloroquine Africa: experience Siaya, Western Kenya,&#226;&#8364;? The <br />             Ring               Merozoites                Subtilisins           American Journal Tropical Medicine Hygiene, vol. 68, no. <br />                                                                                4, pp. 386&#226;&#8364;&#8220;390, 2003. <br />                                                                            [5] C. H. Sibley, J. E. Hyde, P. F. G. Sims et al., &#226;&#8364;&#339;Pyrimethamine- <br />                                                                                sulfadoxine resistance Plasmodium falciparum: next?&#226;&#8364;? <br />                                                                                Trends Parasitology, vol. 17, no. 12, pp. 582&#226;&#8364;&#8220;588, 2001. <br />                                                                            [6] C. Wongsrichanalai, A. L. Pickard, W. H. Wernsdorfer, S. <br />                                             Schizont                           R. Meshnick, &#226;&#8364;&#339;Epidemiology drug-resistant malaria,&#226;&#8364;? Lancet <br />               Trophozoite <br />                                                                                Infectious Diseases, vol. 2, no. 4, pp. 209&#226;&#8364;&#8220;218, 2002. <br />                                  (a)                                       [7] F. Ter Kuile, N. J. White, P. Holloway, G. Pasvol, S. Krishna, <br />                                        Sporozoite                              &#226;&#8364;&#339;Plasmodium falciparum: vitro studies pharmacody- <br />                                                                                namic properties drugs used treatment severe <br />                                        (Rhomboid protease                      malaria,&#226;&#8364;? Experimental Parasitology, vol. 76, no. 1, pp. 85&#226;&#8364;&#8220;95, <br />                                         activity)                              1993. <br />               Liver                                                        [8] N. J. White, &#226;&#8364;&#339;Qinghaosu (artemisinin): price success,&#226;&#8364;? <br />                                                                                Science, vol. 320, no. 5874, pp. 330&#226;&#8364;&#8220;334, 2008. <br />                                        Infected hepatocyte                 [9] W. Ittarat, A. L. Pickard, P. Rattanasinganchan et al., &#226;&#8364;&#339;Recrude- <br />       Liver stage                                                              scence artesunate-treated patients falciparum malaria <br />        schizont                                                                dependent parasite burden parasite factors,&#226;&#8364;? The <br />                                                                                American Journal Tropical Medicine Hygiene, vol. 68, no. <br />           (SUB1                                                                2, pp. 147&#226;&#8364;&#8220;152, 2003. <br />           activity) <br />                                             (SUB1                        [10] M. A. Travassos M. K. Laufer, &#226;&#8364;&#339;Resistance antimalarial <br />                                             activity) <br />                                                                                drugs: molecular, pharmacologic, clinical considerations,&#226;&#8364;? <br />                                                 Release liver stage <br />                                                                                Pediatric Research, vol. 65, no. 5, pp. 64R&#226;&#8364;&#8220;70R, 2009. <br />                                                 merozoites                [11] A. M. Dondorp, F. Nosten, P. Yi et al., &#226;&#8364;&#339;Artemisinin resistance <br />                                                                                Plasmodium falciparum malaria,&#226;&#8364;? New England Journal of <br />                                  (b)                                           Medicine, vol. 361, no. 5, pp. 455&#226;&#8364;&#8220;467, 2009. <br /> Figure 1: Role serine proteases asexual blood stages (a)       [12] T. J. C. Anderson, S. Nair, S. Nkhorna et al., &#226;&#8364;&#339;High heritability <br /> liver stages Plasmodium falciparum (b). Subtilisin-like proteases           malaria parasite clearance rate indicates genetic basis <br /> are essential merozoite invasion egress blood stages, liver         artemisinin resistance western Cambodia,&#226;&#8364;? Journal of <br /> stage schizont development subsequent liver stage merozoite                Infectious Diseases, vol. 201, no. 9, pp. 1326&#226;&#8364;&#8220;1330, 2010. <br /> egress. Rhomboid protease activities supposed involved       [13] WHO, &#226;&#8364;&#339;Global report antimalarial drug efficacy drug <br /> invasion RBC liver.                                                     resistance: 2000&#226;&#8364;&#8220;2010,&#226;&#8364;? 2010. <br />                                                                          [14] WHO, Guidelines Treatment Malaria, 2nd edition, <br />                                                                                2010. <br /> Conflict Interests                                                    [15] B. Turk, &#226;&#8364;&#339;Targeting proteases: successes, failures future <br />                                                                                prospects,&#226;&#8364;? Nature Reviews Drug Discovery, vol. 5, no. 9, pp. 785&#226;&#8364;&#8220; <br /> The author declares conflict interests                     799, 2006. <br /> regarding publication paper.                                 [16] J. H. McKerrow, C. Caffrey, B. Kelly, P. Loke, M. Sajid, <br />                                                                                &#226;&#8364;&#339;Proteases parasitic diseases,&#226;&#8364;? Annual Review Pathology, <br />                                                                                vol. 1, pp. 497&#226;&#8364;&#8220;536, 2006. <br /> Acknowledgments <br />                                                                          [17] M. Drag G. S. Salvesen, &#226;&#8364;&#339;Emerging principles protease- <br /> Data sources PlasmoDB Version 10 gratefully                            based drug discovery,&#226;&#8364;? Nature Reviews Drug Discovery, vol. 9, <br /> acknowledged. The author thankful Professor Athar                        no. 9, pp. 690&#226;&#8364;&#8220;701, 2010. <br /> Chishti, Tufts University, USA, proofreading paper.              [18] C. Flexner, G. Bate, P. Kirkpatrick, &#226;&#8364;&#339;Tipranavir,&#226;&#8364;? Nature <br />                                                                                Reviews Drug Discovery, vol. 4, no. 12, pp. 955&#226;&#8364;&#8220;956, 2005. <br />                                                                          [19] I. Melnikova, &#226;&#8364;&#339;Hepatitis C therapies,&#226;&#8364;? Nature Reviews Drug <br /> References                                                                     Discovery, vol. 7, no. 10, pp. 799&#226;&#8364;&#8220;800, 2008. <br /> [1] J. G. Breman, &#226;&#8364;&#339;The ears hippopotamus: manifestations,         [20] C. G. Smith J. R. Vane, &#226;&#8364;&#339;The discovery captopril,&#226;&#8364;? FASEB <br />     determinants, estimates malaria burden,&#226;&#8364;? The Amer-              Journal, vol. 17, no. 8, pp. 788&#226;&#8364;&#8220;789, 2003. <br />     ican Journal Tropical Medicine Hygiene, vol. 64, no. 1-2,     [21] I. Melnikova, &#226;&#8364;&#339;The anticoagulants market,&#226;&#8364;? Nature Reviews <br />     pp. 1&#226;&#8364;&#8220;11, 2001.                                                            Drug Discovery, vol. 8, no. 5, pp. 353&#226;&#8364;&#8220;354, 2009. <br />  6                                                                                       Interdisciplinary Perspectives Infectious Diseases <br />  <br /> [22] N. Alkhouri N. N. Zein, &#226;&#8364;&#339;Protease inhibitors: silver bullets         [40] M. J. Blackman, H. Fujioka, W. H. L. Stafford et al., &#226;&#8364;&#339;A subtilisin- <br />       chronic hepatitis C infection?&#226;&#8364;? Cleveland Clinic Journal               like protein secretory organelles Plasmodium falciparum <br />       Medicine, vol. 79, no. 3, pp. 213&#226;&#8364;&#8220;222, 2012.                                  merozoites,&#226;&#8364;? Journal Biological Chemistry, vol. 273, no. 36, pp. <br /> [23] A. J. P. Docherty, T. Crabbe, J. P. O&#226;&#8364;&#8482;Connell, C. R. Groom,                23398&#226;&#8364;&#8220;23409, 1998. <br />       &#226;&#8364;&#339;Proteases drug targets,&#226;&#8364;? Biochemical Society Symposium, no.          [41] C. Withers-Martinez, J. W. Saldanha, B. Ely, F. Hackett, T. <br />       70, pp. 147&#226;&#8364;&#8220;161, 2003.                                                        O&#226;&#8364;&#8482;Connor, M. J. Blackman, &#226;&#8364;&#339;Expression recombinant <br /> [24] P. J. Rosenthal, &#226;&#8364;&#339;Hydrolysis erythrocyte proteins proteases              Plasmodium falciparum subtilisin-like protease-1 insect cells. <br />       malaria parasites,&#226;&#8364;? Current Opinion Hematology, vol. 9, no.             Characterization, comparison parasite protease, and <br />       2, pp. 140&#226;&#8364;&#8220;145, 2002.                                                         homology modeling,&#226;&#8364;? Journal Biological Chemistry, vol. 277, <br />                                                                                     no. 33, pp. 29698&#226;&#8364;&#8220;29709, 2002. <br /> [25] M. J. Blackman, &#226;&#8364;&#339;Proteases involved erythrocyte invasion by <br />       malaria parasite: function potential chemotherapeu-          [42] L. Jean, F. Hackett, S. R. Martin, M. J. Blackman, &#226;&#8364;&#339;Func- <br />       tic targets,&#226;&#8364;? Current Drug Targets, vol. 1, no. 1, pp. 59&#226;&#8364;&#8220;83, 2000.           tional characterization propeptide Plasmodium falci- <br />                                                                                     parum subtilisin-like protease-1,&#226;&#8364;? Journal Biological Chem- <br /> [26] S. Yeoh, R. A. O&#226;&#8364;&#8482;Donnell, K. Koussis et al., &#226;&#8364;&#339;Subcellular dis- <br />                                                                                     istry, vol. 278, no. 31, pp. 28572&#226;&#8364;&#8220;28579, 2003. <br />       charge serine protease mediates release invasive malaria <br />       parasites host erythrocytes,&#226;&#8364;? Cell, vol. 131, no. 6, pp. 1072&#226;&#8364;&#8220;     [43] Y. Li, Z. Hu, F. Jordan, M. Inouye, &#226;&#8364;&#339;Functional analysis the <br />       1083, 2007.                                                                   propeptide subtilisin E intramolecular chaperone for <br />                                                                                     protein folding. Refolding inhibitory abilities propeptide <br /> [27] S. Arastu-Kapur, E. L. Ponder, U. P. Fonovi&#194;&#180;c et al., &#226;&#8364;&#339;Identification <br />                                                                                     mutants,&#226;&#8364;? Journal Biological Chemistry, vol. 270, no. 42, pp. <br />       proteases regulate erythrocyte rupture malaria <br />                                                                                     25127&#226;&#8364;&#8220;25132, 1995. <br />       parasite Plasmodium falciparum,&#226;&#8364;? Nature Chemical Biology, vol. <br />       4, no. 3, pp. 203&#226;&#8364;&#8220;213, 2008.                                            [44] H.-W. Huang, W.-C. Chen, C.-Y. Wu et al., &#226;&#8364;&#339;Kinetic studies <br />                                                                                     inhibitory effects propeptides subtilisin BPN&#226;&#8364;&#8482; and <br /> [28] E. Di Cera, &#226;&#8364;&#339;Serine proteases,&#226;&#8364;? IUBMB Life, vol. 61, no. 5, pp. <br />                                                                                     carlsberg bacterial serine proteases,&#226;&#8364;? Protein Engineering, vol. <br />       510&#226;&#8364;&#8220;515, 2009. <br />                                                                                     10, no. 10, pp. 1227&#226;&#8364;&#8220;1233, 1997. <br /> [29] R. J. Siezen J. A. M. Leunissen, &#226;&#8364;&#339;Subtilases: superfamily <br />                                                                               [45] A. Boudreault, D. Gauthier, C. Lazure, &#226;&#8364;&#339;Proprotein con- <br />       subtilisin-like serine proteases,&#226;&#8364;? Protein Science, vol. 6, no. 3, <br />                                                                                     vertase PC1/3-related peptides potent slow tight-binding <br />       pp. 501&#226;&#8364;&#8220;523, 1997. <br />                                                                                     inhibitors murine PC1/3 Hfurin,&#226;&#8364;? Journal Biological <br /> [30] Z. Bozdech, M. Llin&#194;&#180;as, B. L. Pulliam, E. D. Wong, J. Zhu,                     Chemistry, vol. 273, no. 47, pp. 31574&#226;&#8364;&#8220;31580, 1998. <br />       J. L. DeRisi, &#226;&#8364;&#339;The transcriptome intraerythrocytic <br />                                                                               [46] Y. Yabuta, H. Takagi, M. Inouye, U. Shinde, &#226;&#8364;&#339;Folding <br />       developmental cycle Plasmodium falciparum,&#226;&#8364;? PLoS Biology, <br />                                                                                     pathway mediated intramolecular chaperone: propeptide <br />       vol. 1, no. 1, article E5, 2003. <br />                                                                                     release modulates activation precision pro-subtilisin,&#226;&#8364;? Journal <br />  [31] K. G. le Roch, Y. Zhou, P. L. Blair et al., &#226;&#8364;&#339;Discovery gene                Biological Chemistry, vol. 276, no. 48, pp. 44427&#226;&#8364;&#8220;44434, 2001. <br />       function expression profiling malaria parasite life <br />                                                                               [47] M. Fug`ere, P. C. Limperis, V. Beaulieu-Audy et al., &#226;&#8364;&#339;Inhibitory <br />       cycle,&#226;&#8364;? Science, vol. 301, no. 5639, pp. 1503&#226;&#8364;&#8220;1508, 2003. <br />                                                                                     potency specificity subtilase-like pro-protein convertase <br /> [32] M. Llin&#194;&#180;as, Z. Bozdech, E. D. Wong, A. T. Adai, J. L. DeRisi,              (SPC) prodomains,&#226;&#8364;? Journal Biological Chemistry, vol. 277, no. <br />       &#226;&#8364;&#339;Comparative genome transcriptome analysis                     10, pp. 7648&#226;&#8364;&#8220;7656, 2002. <br />       Plasmodium falciparum strains,&#226;&#8364;? Nucleic Acids Research, vol. 34, <br />                                                                               [48] M. J. Gardner, H. Tettelin, D. J. Carucci et al., &#226;&#8364;&#339;Chromosome <br />       no. 4, pp. 1166&#226;&#8364;&#8220;1173, 2006. <br />                                                                                     2 sequence human malaria parasite Plasmodium falci- <br /> [33] M. J. Pallen B. W. Wren, &#226;&#8364;&#339;The HtrA family serine                        parum,&#226;&#8364;? Science, vol. 282, no. 5391, pp. 1126&#226;&#8364;&#8220;1132, 1998. <br />       proteases,&#226;&#8364;? Molecular Microbiology, vol. 26, no. 2, pp. 209&#226;&#8364;&#8220;221, <br />                                                                               [49] E. Pizzi C. Frontali, &#226;&#8364;&#339;Divergence noncoding sequences <br />       1997. <br />                                                                                     insertions encoding nonglobular domains genomic <br /> [34] C. P. Ponting, &#226;&#8364;&#339;Evidence PDZ domains bacteria, yeast,               region conserved plasmodia,&#226;&#8364;? Journal Molecular <br />       plants,&#226;&#8364;? Protein Science, vol. 6, no. 2, pp. 464&#226;&#8364;&#8220;468, 1997.                   Evolution, vol. 50, no. 5, pp. 474&#226;&#8364;&#8220;480, 2000. <br /> [35] N. D. Rawlings, E. O&#226;&#8364;&#8482;Brien, A. J. Barrett, &#226;&#8364;&#339;MEROPS:              [50] L. Jean, C. Withers-Martinez, F. Hackett, M. J. Blackman, <br />       protease database,&#226;&#8364;? Nucleic Acids Research, vol. 30, no. 1, pp.               &#226;&#8364;&#339;Unique insertions Plasmodium falciparum subtilisin- <br />       343&#226;&#8364;&#8220;346, 2002.                                                                like protease-1 crucial enzyme maturation activity,&#226;&#8364;? <br /> [36] P. K. Harris, S. Yeoh, A. R. Dluzewski et al., &#226;&#8364;&#339;Molecular                      Molecular Biochemical Parasitology, vol. 144, no. 2, pp. 187&#226;&#8364;&#8220; <br />       identification malaria merozoite surface sheddase,&#226;&#8364;? PLoS                 197, 2005. <br />       Pathogens, vol. 1, no. 3, article e29, pp. 0241&#226;&#8364;&#8220;0251, 2005.              [51] S. Gemma, S. Giovani, M. Brindisi et al., &#226;&#8364;&#339;Quinolylhydrazones <br /> [37] A. Alam, R. K. Bhatnagar, V. S. Chauhan, &#226;&#8364;&#339;Expression                   novel inhibitors Plasmodium falciparum serine protease <br />       characterization catalytic domain Plasmodium falciparum                 PfSUB1,&#226;&#8364;? Bioorganic &amp; Medicinal Chemistry Letters, vol. 22, no. <br />       subtilisin-like protease 3,&#226;&#8364;? Molecular Biochemical Parasitol-             16, pp. 5317&#226;&#8364;&#8220;5321, 2012. <br />       ogy, vol. 183, no. 1, pp. 84&#226;&#8364;&#8220;89, 2012.                                  [52] A. Ruecker, M. Shea, F. Hackett, C. Suarez, E. M. A. Hirst, <br /> [38] A. Alam, R. K. Bhatnagar, U. Relan, P. Mukherjee, V.                       K. Milutinovic, &#226;&#8364;&#339;Proteolytic activation essential <br />       S. Chauhan, &#226;&#8364;&#339;Proteolytic activity Plasmodium falciparum                    parasitophorous vacuole cysteine protease SERA6 accompanies <br />       subtilisin-like protease 3 parasite profilin, multifunctional            malaria parasite egress host erythrocyte,&#226;&#8364;? The Journal of <br />       protein,&#226;&#8364;? Molecular Biochemical Parasitology, vol. 191, no. 2,            Biological Chemistry, vol. 287, no. 45, pp. 37949&#226;&#8364;&#8220;37963, 2012. <br />       pp. 58&#226;&#8364;&#8220;62, 2013.                                                        [53] M. J. Blackman, H.-G. Heidrich, S. Donachie, J. S. McBride, <br /> [39] M. Sajid, C. Withers-Martinez, M. J. Blackman, &#226;&#8364;&#339;Matu-                      A. A. Holder, &#226;&#8364;&#339;A single fragment malaria merozoite <br />       ration specificity Plasmodium falciparum subtilisin-like               surface protein remains parasite red cell invasion <br />       protease-1, malaria merozoite subtilisin-like serine protease,&#226;&#8364;?             target invasion-inhibiting antibodies,&#226;&#8364;? Journal of <br />       Journal Biological Chemistry, vol. 275, no. 1, pp. 631&#226;&#8364;&#8220;641, 2000.          Experimental Medicine, vol. 172, no. 1, pp. 379&#226;&#8364;&#8220;382, 1990. <br />  Interdisciplinary Perspectives Infectious Diseases                                                                                              7 <br />  <br /> [54] V. K. Goel, X. Li, H. Chen, S.-C. Liu, A. H. Chishti, S. S.         [68] F. Hackett, M. Sajid, C. Withers-Martinez, M. Grainger, and <br />       Oh, &#226;&#8364;&#339;Band 3 host receptor binding merozoite surface protein            M. J. Blackman, &#226;&#8364;&#339;PfSUB-2: second subtilisin-like protein in <br />       1 Plasmodium falciparum invasio <br /> </body></html>